This article summarized the latest R&D progress of Idarucizumab, the Mechanism of Action for Idarucizumab, and the drug target R&D trends for Idarucizumab.

Oscotec Inc. and ADEL Inc. has announced that the FDA has given the IND application approval for ADEL-Y01 to be used in the treatment of Alzheimer's Disease.

This article summarized the latest R&D progress of Glofitamab, the Mechanism of Action for Glofitamab, and the drug target R&D trends for Glofitamab

Human Epidermal Growth Factor Receptor 2 (HER2) is a member of the EGFR kinase family, which also includes HER1, HER3, and HER4.

This article summarized the latest R&D progress of Fezolinetant, the Mechanism of Action for Fezolinetant, and the drug target R&D trends for Fezolinetant.

Nektar Therapeutics disclosed fresh clinical results concerning rezpegaldesleukin utilised for patients battling atopic dermatitis, featuring new clinical effectiveness parameters from its Phase 1b research.

This article summarized the latest R&D progress of Faricimab, the Mechanism of Action for Faricimab, and the drug target R&D trends for Faricimab.

HDAC (Histone Deacetylase), otherwise known as a histone deacetylase, is an important type of enzyme involved in the process of histone modifications.

This article summarized the latest R&D progress of Entrectinib, the Mechanism of Action for Entrectinib, and the drug target R&D trends for Entrectinib.

Coeptis Therapeutics delivers an update on the safety and dosage from Phase 1 Trials of DVX201, intended for those with Relapsed/Refractory AML or High Risk MDS.

This article summarized the latest R&D progress of Daprodustat, the Mechanism of Action for Daprodustat, and the drug target R&D trends for Daprodustat.

GnRHR, or Gonadotropin-Releasing Hormone Receptor, plays a crucial role in the human body's reproductive system.